Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku Tokyo, Japan.
Department of Dermatologic Oncology, National Cancer Center Hospital, Chuo-ku Tokyo, Japan.
Skin Res Technol. 2023 Jan;29(1):e13243. doi: 10.1111/srt.13243. Epub 2022 Nov 20.
Scalp angiosarcoma is a rare and aggressive cancer. Definitive radiotherapy is a treatment option for localised scalp angiosarcoma patients. Although definitive surgical resection reportedly prolongs overall survival (OS), whether initial local treatment effect affects OS when definitive radiotherapy is administered is unclear. Therefore, this study analysed whether local recurrence within 6 months of irradiation correlates with OS and cancer-specific survival (CSS). Furthermore, how local control affects patients' quality of life was investigated.
Thirty-one localised scalp angiosarcoma patients who had received definitive radiotherapy at our institution between October 2010 and July 2021 were analysed retrospectively. The most commonly used dose fractionation was 70 Gy in 35 fractions (83.9%). Local recurrence within 6 months of radiotherapy and other clinical factors were examined in univariate and subsequent multivariate analyses for correlation with OS and CSS.
The median follow-up period was 16 months (range, 6-45 months). Local recurrence was detected in 16 patients (51.6%), 12 of whom had recurrence within 6 months. In multivariate analyses, the presence of local recurrence within 6 months of radiotherapy was significantly associated with OS and CSS (p = 0.003, 0.0001, respectively). Ten of the 16 patients with local recurrence had severe symptoms such as bleeding, pain, difficulty opening the eye and malodour.
The initial local treatment effect was significantly associated with OS and CSS after definitive radiotherapy. Furthermore, local recurrence after radiotherapy resulted in a variety of symptoms, including bleeding and pain, which reduced the patient's quality of life.
头皮血管肉瘤是一种罕见且侵袭性强的癌症。对于局限性头皮血管肉瘤患者,确定性放疗是一种治疗选择。虽然据报道,根治性手术切除可延长总生存期(OS),但在给予确定性放疗时,初始局部治疗效果是否影响 OS 尚不清楚。因此,本研究分析了放疗后 6 个月内的局部复发是否与 OS 和癌症特异性生存(CSS)相关。此外,还研究了局部控制如何影响患者的生活质量。
回顾性分析了 2010 年 10 月至 2021 年 7 月期间在我院接受确定性放疗的 31 例局限性头皮血管肉瘤患者。最常用的剂量分割方式为 70 Gy/35 次(83.9%)。在单变量和随后的多变量分析中,检查放疗后 6 个月内的局部复发和其他临床因素与 OS 和 CSS 的相关性。
中位随访时间为 16 个月(范围 6-45 个月)。16 例患者(51.6%)检测到局部复发,其中 12 例在 6 个月内复发。在多变量分析中,放疗后 6 个月内出现局部复发与 OS 和 CSS 显著相关(p=0.003,0.0001)。16 例局部复发患者中有 10 例出现严重症状,如出血、疼痛、睁眼困难和恶臭。
初始局部治疗效果与根治性放疗后的 OS 和 CSS 显著相关。此外,放疗后局部复发导致多种症状,包括出血和疼痛,降低了患者的生活质量。